NCT01559961View on ClinicalTrials.gov

Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

June 30, 2013

Conditions
Interstitial Cystitis
Interventions
DRUG

TTI-1612

Single intravesical 30-minute treatments with escalating doses of TTI-1612.

Trial Locations (4)

L6T 4S5

Bramalea Medical Centre, Brampton

N2N 2B9

Urology Associates/Urologic Medical Research, Kitchener

L6H 3P1

The Fe/Male Health Centres, Oakville

M1S 4V5

Urology & Male Fertility Clinic, Toronto

All Listed Sponsors
lead

Trillium Therapeutics Inc.

INDUSTRY

NCT01559961 - Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome | Biotech Hunter | Biotech Hunter